

# Table of Contents

## CHAPTER 1. THE CONTROLLED SUBSTANCES ACT

- § 1:1 Introduction and history
- § 1:2 Overview
- § 1:3 The Drug Enforcement Administration
- § 1:4 Constitutionality of classifications
- § 1:5 Constitutionality of scheduling authority
- § 1:6 Scheduling criteria: Overview
- § 1:7 Scheduling procedure: Overview
- § 1:8 Length of scheduling procedures
- § 1:9 Temporary scheduling
- § 1:10 Scheduling findings: Potential for abuse
- § 1:11 Scheduling findings: accepted medical use
- § 1:12 Scheduling findings: Safety and dependence
- § 1:13 Balancing the three scheduling criteria
- § 1:14 The relevance of cost and access to medicine in scheduling determinations
- § 1:15 The role of health and human services findings in scheduling
- § 1:16 Scheduling and U.S. treaty obligations
- § 1:17 Challenging scheduling determinations and DEA rules
- § 1:18 The effect of the Department of Justice's non-enforcement policy on marijuana's Schedule I status
- § 1:19 The Controlled Substances Act's regulatory provisions: overview
- § 1:20 Registration
- § 1:21 Security
- § 1:22 Quotas
- § 1:23 Order forms
- § 1:24 Records and inventory
- § 1:25 Labels and packaging
- § 1:26 Prescribing
- § 1:27 Research of Schedule I substances
- § 1:28 The relationship between the Controlled Substances Act and the Food, Drug, and Cosmetic Act
- § 1:29 The Controlled Substances Act and Drug sentencing
- § 1:30 State enactment of the Uniform Controlled Substances Act
- § 1:31 Scheduling under the Uniform Controlled Substances Act: overview

- § 1:32 Scheduling under the Uniform Controlled Substances Act: procedure
- § 1:33 Scheduling under the Uniform Controlled Substances Act: scheduling criteria
- § 1:34 States employing the Uniform Controlled Substances Act's scheduling criteria
- § 1:35 States employing modified versions of the Uniform Controlled Substances Act's scheduling criteria
- § 1:36 States employing unique classification schemes
- § 1:37 Regulation under the Uniform Controlled Substances Act
- § 1:38 State prosecution of physicians
- § 1:39 Substance-specific laws
- § 1:40 Alterations to controlled substances regulations during the coronavirus pandemic

## **CHAPTER 2. ADDICTION TO DRUGS**

- § 2:1 Generally
- § 2:2 Drug abuse and addiction as public health problems
- § 2:3 What matters in addiction
- § 2:4 Addiction is a brain disease
- § 2:5 But not just a brain disease
- § 2:6 A chronic, relapsing disorder
- § 2:7 Conclusion
- § 2:8 Brain systems affected by addiction
- § 2:9 Diagnostic criteria for drug addiction
- § 2:10 Criminal punishment of addiction
- § 2:11 Civil commitment of drug addicts—The Federal Narcotic Addict Rehabilitation Act of 1966
- § 2:12 —The California Civil Addict Program [CAP]
- § 2:13 —Other State Civil Commitment Programs
- § 2:14 Treatment of addiction by physicians

## **CHAPTER 3. COMMONLY ABUSED DRUGS**

### **I. INTRODUCTION**

- § 3:1 Generally

### **II. NARCOTIC DRUGS**

- § 3:2 Historical perspective
- § 3:3 The opium poppy
- § 3:4 Opium derivatives
- § 3:5 Morphine
- § 3:6 Codeine
- § 3:7 Thebaine

## TABLE OF CONTENTS

§ 3:8	Semi-synthetic narcotics
§ 3:9	—Heroin
§ 3:10	—Hydromorphone
§ 3:11	—Oxycodone
§ 3:12	—Etorphine and Diprenorphine
§ 3:13	Methadone and other synthetic narcotics
§ 3:14	Narcotic antagonists
§ 3:15	Addiction to narcotic drugs
§ 3:16	Methadone maintenance programs
§ 3:17	Prescribing buprenorphine for addict maintenance
§ 3:18	Confidentiality of methadone patient treatment records
§ 3:19	Narcotic overdose deaths
§ 3:20	Heroin trafficking in the United States
§ 3:21	—South American heroin
§ 3:22	—Mexican heroin
§ 3:23	—Southeast Asian heroin
§ 3:24	—Southwest Asian heroin
§ 3:25	—Purity
§ 3:26	Prices
§ 3:27	Seizures

## III. STIMULANT DRUGS

§ 3:28	Historical perspective
§ 3:29	Cocaine
§ 3:30	Cocaine deaths
§ 3:31	Efforts to eradicate coca cultivation
§ 3:32	Cocaine use during pregnancy
§ 3:33	Crack cocaine sentencing disparity
§ 3:34	Amendment of Federal Sentencing Guidelines for crack
§ 3:35	The Fair Sentencing Act of 2010
§ 3:36	Cathinone (khat)
§ 3:37	MDMA (Ecstasy)
§ 3:38	Bath salts
§ 3:39	Medical use of amphetamines
§ 3:40	Treatment of ADHD
§ 3:41	Methamphetamine
§ 3:42	Cocaine trafficking in the United States
§ 3:43	—Trafficking by Colombian and Mexican Organizations
§ 3:44	—Crack cocaine trafficking
§ 3:45	—Prices and purity
§ 3:46	—Seizures
§ 3:47	Methamphetamine trafficking in the United States
§ 3:48	—Purity
§ 3:49	—Prices

- § 3:50 —Seizures
- § 3:51 MDMA trafficking in the United States

#### IV. DEPRESSANT DRUGS

- § 3:52 Historical perspective
- § 3:53 Medical use and abuse of depressant drugs
- § 3:54 —Benzodiazepines
- § 3:55 —Non-benzodiazepine sleep medications
- § 3:56 —Barbiturates
- § 3:57 —Glutethimide
- § 3:58 —Methaqualone
- § 3:59 —Flunitrazepam
- § 3:60 —Gamma Hydroxybutyrate (GHB)
- § 3:61 Abuse of prescription drugs by youth
- § 3:62 Impairment of driving skills by depressant drugs
- § 3:63 The impact of criminal sanctions upon depressant abuse
- § 3:64 Flunitrazepam trafficking in the United States

#### V. CANNABIS

- § 3:65 The cannabis plant
- § 3:66 Historic use of cannabis
- § 3:67 Historic use of Cannabis—Biblical references
- § 3:68 Historic use of cannabis—China
- § 3:69 —India
- § 3:70 —Africa
- § 3:71 —Brazil
- § 3:72 —Jamaica
- § 3:73 Early regulation of cannabis
- § 3:74 Measuring current use of cannabis
- § 3:75 Research demonstrating adverse health consequences of cannabis
- § 3:76 Research demonstrating potential therapeutic benefits of cannabis
- § 3:77 Efforts to eradicate cannabis cultivation
- § 3:78 Industrial hemp
- § 3:79 Legal definition of marijuana
- § 3:80 Classification of marijuana as a narcotic
- § 3:81 Definition of hashish
- § 3:82 Edible marijuana
- § 3:83 Marijuana Dabbing
- § 3:84 Congressional classification of marijuana on Schedule I
- § 3:85 Attempts to administratively reclassify marijuana
- § 3:86 Limitation of the medical necessity defense
- § 3:87 The California medicinal marijuana law

## TABLE OF CONTENTS

- § 3:88 Medical marijuana laws in other states and Canada
- § 3:89 State legalization of recreational use
- § 3:90 Growth and regulation of the cannabis industry
- § 3:91 SAFE Banking Act
- § 3:92 Federal acceptance of state marijuana legalization
- § 3:93 Collateral consequences of continued illegality
- § 3:94 Harassment of physicians who recommend medical marijuana
- § 3:95 Federal immunity of state officers enforcing state marijuana laws
- § 3:96 Use of medical marijuana by probationers
- § 3:97 Marijuana trafficking in the United States
- § 3:98 —Domestic marijuana
- § 3:99 —Mexican marijuana
- § 3:100 —Canadian marijuana
- § 3:101 —Prices and potency (THC content)
- § 3:102 —Seizures
- § 3:103 Prosecution for cultivation of marijuana

## VI. HALLUCINOGENS

- § 3:104 Historical perspective
- § 3:105 Hallucinogens and dissociative drugs
- § 3:106 LSD
- § 3:107 Peyote (Mescaline)
- § 3:108 Psilocybin (magic mushrooms)
- § 3:109 Salvia divinorum
- § 3:110 Bufotenine and Dermorphin
- § 3:111 Phencyclidine (PCP)
- § 3:112 Ketamine
- § 3:113 Dextromethorphan (DXM)
- § 3:114 LSD and PCP trafficking in the United States

## VII. INHALANTS

- § 3:115 Historical perspective
- § 3:116 Frequently abused inhalants
- § 3:117 Prevalence of use of inhalants
- § 3:118 State regulation of inhalants

## VIII. ALCOHOL

- § 3:119 Historical perspective
- § 3:120 The costs of alcohol abuse
- § 3:121 —Health care costs
- § 3:122 The Costs of alcohol abuse—Productivity losses
- § 3:123 The costs of alcohol abuse—Losses from premature deaths

- § 3:124 —Crime-related productivity losses
- § 3:125 —Other impacts
- § 3:126 —Limitations and caveats
- § 3:127 Legal regulation of alcohol distribution and consumption
- § 3:128 The genetics of alcoholism
- § 3:129 —Vulnerability to alcoholism
- § 3:130 —Alcohol dependence
- § 3:131 —Adoption studies
- § 3:132 —Personality traits
- § 3:133 —Specific genes
- § 3:134 —Alcohol-related behaviors
- § 3:135 Underage drinking
- § 3:136 Interaction of alcohol with other drugs
- § 3:137 Treatment alternatives

## **IX. NICOTINE**

- § 3:138 Historical perspective
- § 3:139 Current prevalence of smoking
- § 3:140 —methods
- § 3:141 —Results
- § 3:142 —Conclusions and comment
- § 3:143 Secondhand smoke exposure
- § 3:144 Nicotine addiction
- § 3:145 Liability of tobacco companies
- § 3:146 The master settlement agreement
- § 3:147 The federal suit against tobacco companies

## **X. STEROIDS**

- § 3:148 Historical perspective
- § 3:149 Health consequences of steroid abuse
- § 3:150 Legal regulation of steroids
- § 3:151 —The anabolic steroid control act of 2004
- § 3:152 —Changes to exclusionary language of 21 U.S.C.A. § 811(g)
- § 3:153 —Impact of the changes
- § 3:154 —The Drug Free Sports Act of 2005
- § 3:155 Steroids in professional baseball: the Mitchell report
- § 3:156 Testing for steroid use
- § 3:157 —The World Anti-Doping Code
- § 3:158 —Criticism of current testing techniques
- § 3:159 Legal defense of steroid prosecutions
- § 3:160 Steroid trafficking in the United states

## **XI. DESIGNER DRUGS**

- § 3:161 Historical perspective

## TABLE OF CONTENTS

- § 3:162 The Controlled Substances Analogue Enforcement Act of 1986
- § 3:163 Delegation of emergency scheduling powers

## **CHAPTER 4. DRUGS IN THE WORKPLACE**

- § 4:1 Drug testing of public employees and job applicants: Overview
- § 4:2 Drug testing of public employees—Law enforcement officers and firefighters
  - § 4:3 —Elected officials
- § 4:4 Drug testing of private employees
- § 4:5 The Drug-Free Workplace Act of 1988
- § 4:6 Drug testing of students
- § 4:7 Reliability of drug testing procedures—Urine testing
  - § 4:8 —EMIT tests
  - § 4:9 —Securing the urine sample
- § 4:10 Employment discrimination—Methadone patients
  - § 4:11 —Medical marijuana patients
- § 4:12 Members of the armed services

## **CHAPTER 5. PROVING THE IDENTITY OF DRUGS**

- § 5:1 Introduction
- § 5:2 Establishing probable cause—Justice Peters' cookies
  - § 5:3 —Street sale transactions
  - § 5:4 —Automobile passengers
  - § 5:5 —Search of home
  - § 5:6 —Bindles, balloons and baggies
  - § 5:7 —Plain view
  - § 5:8 —Plain feel
  - § 5:9 —Plain smell
  - § 5:10 —Alert by trained dog sniffers to automobiles
  - § 5:11 —Alert of drug sniffing dog to cocaine
  - § 5:12 —Dog sniffing of homes
  - § 5:13 —Dog sniffing of bus passengers and students
  - § 5:14 —Dog sniffing of closed containers
  - § 5:15 —Challenging the reliability of drug sniffing dogs
  - § 5:16 —Opening closed containers
- § 5:17 Chain of custody of seized drugs
  - § 5:18 —The Constitutional Right of Confrontation of Witnesses
- § 5:19 Identification of drugs by lay opinions and circumstantial evidence
- § 5:20 Identification of drugs by field tests
- § 5:21 Identification of drugs by laboratory tests
- § 5:22 Defendant's right to independent laboratory analysis

- § 5:23 Laboratory testing for cocaine—L-cocaine vs. D-cocaine
- § 5:24 —“Cocaine Base”
- § 5:25 Laboratory testing for marijuana
- § 5:26 Laboratory testing of hair samples
- § 5:27 Sweatpatch testing
- § 5:28 The effect of the legalization of hemp on proving the identity of a substance

## **CHAPTER 6. COMPETENCY, MENS REA, INSANITY**

- § 6:1 Introduction
- § 6:2 Forensic psychopharmacology: The drug expert in court
- § 6:3 Competency to stand trial
- § 6:4 The voluntariness of out-of-court confessions
- § 6:5 Competency of witnesses
- § 6:6 Restoration of competency by involuntary medication
- § 6:7 Delusional patients
- § 6:8 Forced medication as a condition of supervised release
- § 6:9 “Voluntary” vs. “involuntary” intoxication as a defense
- § 6:10 Drug use, unconsciousness and “settled insanity”

# Table of Contents

## CHAPTER 7. POSSESSORY OFFENSES

- § 7:1 Introduction
- § 7:2 Possession as control
- § 7:3 Simultaneous possession of multiple drugs
- § 7:4 Simultaneous possession of same drug in different locations
- § 7:5 Possession pursuant to a valid prescription
- § 7:6 Attempted possession
- § 7:7 Possession for purpose of disposal
- § 7:8 Immunity for overdose victims
- § 7:9 Internal possession of consumed drugs
- § 7:10 Constructive possession of drugs in a shared residence
- § 7:11 Constructive possession of drugs in an automobile
- § 7:12 Proof of knowledge required for possession
- § 7:13 Deliberate ignorance
- § 7:14 Requirement of a usable quantity
- § 7:15 Proving weight or quantity when it is an element of the crime
- § 7:16 Knowledge of possession of the requisite quantity

## CHAPTER 8. TRAFFICKING OFFENSES

- § 8:1 Introduction
- § 8:2 The offense of possession with intent to distribute
- § 8:3 Expert testimony by police to establish intent to distribute
- § 8:4 “Overview” testimony by investigating drug agents
- § 8:5 Joint purchasers sharing drugs: The *Swiderski* defense
- § 8:6 Distribution or sale of drugs
- § 8:7 Aggravated sales: the “Kingpin” law
- § 8:8 Use of communication facilities to facilitate drug offenses
- § 8:9 Drug distribution to minors
- § 8:10 The schoolyard enhancement
- § 8:11 “Look-alike” drugs and counterfeit sales
- § 8:12 Attempt, solicitation and conspiracy to buy or sell drugs
- § 8:13 —Attempt
- § 8:14 —Solicitation
- § 8:15 —Conspiracy
- § 8:16 —Multiple conspiracies and the distribution chain
- § 8:17 —Participation of government agents or informants

- § 8:18 —Sentencing issues
- § 8:19 —State conspiracy prosecutions
- § 8:20 Drug smuggling: Extraterritorial jurisdiction
- § 8:21 Presence where drugs are being used
- § 8:22 Providing drugs that cause death

## **CHAPTER 9. CONTROL OF LAW ENFORCEMENT TECHNIQUES**

- § 9:1 Use of informants in drug cases
- § 9:2 Motions to Require Disclosure or Production of an Informant
- § 9:3 Contingent Payments to Informants
- § 9:4 Supplying Informants with Drugs
- § 9:5 Standing to Challenge Unlawful Arrests of Informants
- § 9:6 The Informant's Right to Counsel
- § 9:7 Use of Juvenile Informants
- § 9:8 Enrollment of police informants in drug treatment programs
- § 9:9 Reliability of Addicts as Informants
- § 9:10 Use of enhanced surveillance
- § 9:11 Use of "Drug Profiles"
- § 9:12 Use of drug interdiction roadblocks
- § 9:13 Use of search warrants
- § 9:14 Entry to Execute Search Warrants Without Knocking
- § 9:15 Forcible Recovery of Concealed Drugs
- § 9:16 The Problem of Police Perjury
- § 9:17 The military's role in the war on drugs
- § 9:18 Prioritizing police and prosecutorial discretion

## **CHAPTER 10. AFFIRMATIVE DEFENSES IN DRUG CASES**

- § 10:1 Selective prosecution
- § 10:2 Prosecutorial discretion to manipulate sentencing alternatives
- § 10:3 Discovery motions to gain access to evidence of discriminatory prosecution
- § 10:4 The entrapment defense: The federal subjective predisposition test and outrageous government conduct
- § 10:5 Proving and challenging predisposition
- § 10:6 The burden of proof in entrapment cases
- § 10:7 Acceptance of the objective "outrageous conduct" test by state courts
- § 10:8 Non-governmental inducement
- § 10:9 Requirement of admission of offense to assert entrapment defense

## TABLE OF CONTENTS

- § 10:10 Entrapment defense in administrative proceedings
- § 10:11 The selection of targets for inducement
- § 10:12 Entrapment by estoppel, public authority and innocent intent
- § 10:13 Sentencing entrapment and sentencing manipulation
- § 10:14 Religious freedom as a defense to possession of peyote
- § 10:15 The Religious Freedom Restoration Act
- § 10:16 Religious freedom as a defense to possession of drugs other than peyote
- § 10:17 Meeting the requirement that religious belief is “bona fide”
- § 10:18 Religious freedom to refuse mandated participation in AA Programs
- § 10:19 Religious freedom as a defense to charges of drug distribution
- § 10:20 Right of privacy as a defense to drug possession
- § 10:21 The privacy of patient medical records
- § 10:22 Is there a privacy right to self-medication?
- § 10:23 Unconstitutional overbreadth and vagueness: drug paraphernalia laws
- § 10:24 Unconstitutional vagueness in defining controlled substances
- § 10:25 Unconstitutional vagueness of drug-traffic loitering statutes

## **CHAPTER 11. FORFEITURE**

- § 11:1 Asset forfeiture in drug cases: Background and overview
- § 11:2 The civil asset forfeiture reform act of 2000: Procedures and overview
- § 11:3 Comparison of state asset forfeiture laws
- § 11:4 Types of property subject to forfeiture: Overview
- § 11:5 Forfeiture of conveyances: Federal decisions
- § 11:6 Forfeiture of conveyances: state decisions
- § 11:7 Forfeiture of proceeds: Federal decisions
- § 11:8 Forfeiture of proceeds: state court decisions
- § 11:9 Forfeiture of real property
- § 11:10 Forfeiture and the right to counsel
- § 11:11 Interaction between civil forfeiture and criminal prosecutions
- § 11:12 The innocent owner defense
- § 11:13 Double jeopardy challenges to forfeiture laws
- § 11:14 The Eighth Amendment and forfeiture
- § 11:15 Application of the Fourth Amendment to forfeiture proceedings

## **CHAPTER 12. IMMIGRATION CONSEQUENCES**

- § 12:1 Duty to advise

- § 12:2 Drug offenses triggering deportation
- § 12:3 Effect of expungement pursuant to state marijuana legalization law

### **CHAPTER 13. CIVIL SANCTIONS**

- § 13:1 Eviction from public housing
- § 13:2 Suspension or revocation of driving privileges
- § 13:3 Denial of government benefits
- § 13:4 Drug testing of welfare recipients
- § 13:5 Ban on student aid
- § 13:6 Exclusion from “drug free zones”
- § 13:7 “RAVE act” civil penalties
- § 13:8 The Drug Dealer Liability Act
- § 13:9 Suspension or expulsion from public school
- § 13:10 Limitation of right to possess firearms

### **CHAPTER 14. SENTENCING ALTERNATIVES**

- § 14:1 The constitutional prohibition of cruel and unusual punishment
- § 14:2 The Rockefeller drug laws in New York
- § 14:3 The right to a jury determination of facts used to increase sentence
- § 14:4 Diversion and deferred entry of judgment
- § 14:5 California Proposition 36
- § 14:6 California proposition 47
- § 14:7 Probation and parole for drug offenders
- § 14:8 Drug treatment in prisons
- § 14:9 Introducing contraband drugs into prisons or jails

### **CHAPTER 15. FEDERAL SENTENCING**

- § 15:1 Background and overview
- § 15:2 An introduction to mandatory minimum drug sentencing
- § 15:3 Mandatory minimum penalties based on drug quantity
- § 15:4 Requirement to prove drug quantity to a jury beyond a reasonable doubt
- § 15:5 Application of mandatory minimums to peripheral participants
- § 15:6 Is knowledge of drug type and quantity required to trigger a mandatory minimum?
- § 15:7 Drug quantities from separate counts are not aggregated
- § 15:8 Mandatory minimum enhancements for recidivists
- § 15:9 Recidivist enhancements must be sought by the prosecutor

## TABLE OF CONTENTS

- § 15:10 Proving the fact of a prior conviction
- § 15:11 “Serious drug offense” and “felony drug offense” for purposes of recidivist enhancements
- § 15:12 Convictions “relating to narcotic drugs”
- § 15:13 Juvenile adjudications and recidivist enhancements
- § 15:14 Prior drug convictions that have been expunged under a diversion program and recidivist enhancements
- § 15:15 “A violation after a prior conviction . . . has become final”
- § 15:16 Enhanced mandatory minimum penalties if death or serious bodily injury results from use of the controlled substance
- § 15:17 The armed career criminal act and mandatory minimum drug sentencing
- § 15:18 State offenses “involving manufacturing, distributing, or possessing with intent to distribute, a controlled substance” under The Armed Career Criminal Act
- § 15:19 Use of firearms in connection with drug trafficking under the Armed Career Criminal Act: Section 924(c)
- § 15:20 Section 924(c)’s “second or subsequent conviction” enhancement
- § 15:21 The “safety valve”: Background and overview
- § 15:22 The “safety valve” criminal history requirement
- § 15:23 The “safety valve” absence of violence or possession of a weapon requirement
- § 15:24 The “safety valve” death or bodily injury limitation
- § 15:25 The “safety valve” leader or manager limitation
- § 15:26 The “safety valve” requirement to truthfully provide information
- § 15:27 Form of “safety valve” disclosure and affirmative duty to disclose
- § 15:28 Timing of “safety valve” disclosures
- § 15:29 “Safety valve” compliance is determined by the court
- § 15:30 “Safety valve” burden of proving complete and truthful disclosure
- § 15:31 Scope of the “safety valve” disclosure requirement
- § 15:32 “Safety valve” standard of truthfulness
- § 15:33 “Safety valve” duty to disclose does not violate the Fifth Amendment
- § 15:34 The “safety valve” applies only to specified drug offenses
- § 15:35 The “safety valve” statute and the sentencing guidelines
- § 15:36 The “safety valve” and ineffective assistance of counsel
- § 15:37 The department of justice’s mandatory minimum sentences charging policy

- § 15:38 The federal sentencing guidelines: background and overview
- § 15:39 Constitutionality and application of the Guidelines after *Booker*
- § 15:40 U.S.S.G § 2D1.1(c)'s drug quantity table
- § 15:41 The 2014 “drugs minus two” amendment and U.S.S.G. § 2D1.1(c)'s pre- amendment drug quantity table
- § 15:42 Determining drug type under the guidelines
- § 15:43 Calculating drug quantity under the guidelines: Overview
- § 15:44 Mixture or substance
- § 15:45 Scope of an individual’s relevant drug quantities
- § 15:46 Attributing quantities for jointly undertaken criminal activity
- § 15:47 Unconsummated transactions
- § 15:48 Estimating un-seized drug quantities
- § 15:49 Stipulations as to drug quantity
- § 15:50 Equivalency tables and calculations with multiple drug types
- § 15:51 Non-guidelines sentences based on disagreement with the drug quantity table
- § 15:52 Specific offense characteristics and adjustments
- § 15:53 Adjustment if a dangerous weapon was possessed
- § 15:54 Aggravating role adjustment
- § 15:55 The career offender guideline
- § 15:56 Mitigating role adjustment
- § 15:57 Substantial assistance
- § 15:58 Non-guidelines sentences and departures based on the history and characteristics of the defendant in drug cases: addiction and rehabilitation
- § 15:59 Non-guidelines sentences and departures based on state marijuana legalization and federal non-enforcement of marijuana laws
- § 15:60 Non-guidelines sentences based on the need to avoid a disparity in sentencing the participants in a drug organization
- § 15:61 Downward departures for extraordinary circumstances
- § 15:62 Drug treatment in federal prisons
- § 15:63 Supervised release of federal drug defendants
- § 15:64 Clemency Project 2014
- § 15:65 The Formerly Incarcerated Reenter Society Transformed Safely Transitioning Every Person Act (FIRST STEP Act)

## **CHAPTER 16. DRUG COURTS**

- § 16:1 Historical establishment and development

TABLE OF CONTENTS

§ 16:2 Assignment of defendants to drug courts  
§ 16:3 Treatment alternatives  
§ 16:4 Termination and due process  
§ 16:5 Federal drug courts  
§ 16:6 Evidence regarding the efficacy of drug courts  
§ 16:7 Drug decriminalization treatment regimes

**Table of Cases**

**Index**